PPT-Sofosbuvir-Velpatasvir-Voxilaprevir

in DAA Naïve GT 16 POLARIS2 Phase 3 Treatment Naïve and Treament Experienced DAA Naïve Jacobson IM et al Gastroenterology 201715311322 Source Jacobson IM et al Gastroenterology 201715311322. + Sofosbuvir in HCV GT 1-4 and HIV Coinfection. ALLY-2 Study. Phase 3. . Treatment. -. Naïve . and . Treatment-Experienced. Wyles. DL, . et al. . N . Engl. J Med. 2015;373:714-25.. Source: . Wyles. Hepatitis-2015. Orlando. , USA. July 20 - 22 2015. The Growing Epidemic in HCC from Hepatitis/NASH Cirrhosis in American Veterans. Implications and Economic burdens for the Health Care in the United States and the World!. (. Epclusa. ). Prepared by. : H. Nina Kim, MD MSc and David . Spach. , MD. Last . Updated: . July . 8, . 2016. Background and Dosing. Sofosbuvir-Velpatasvir. (. Epclusa. ). Sofosbuvir-Velpatasvir. (. Matthew Luu, Yuan Fang (Pearl) Cai, Shiming Sun, . Ziyi Cheng. PHM142 Fall . 2016. Coordinator. : Dr. Jeffrey Henderson. Instructor: Dr. David Hampson. What is Hepatitis C? . Flaviviridae. virus family. ION-4. Phase . 3. Treatment. Naïve and Treatment . Experienced. Naggie. S, . et al. . N . Engl. J Med 2015;378:705-13.. HIV Coinfection. Source: . Naggie. S, et al. N . Engl. J Med 2015;378:705-13.. NIH SPARE. Phase . 2. Treatment. . Naïve . (unfavorable baseline treatment . characteristics). Osinusi. A, et al. JAMA. 2013;310:804-11.. Source: . Osinusi. A,. . et al. . JAMA. 2013;310:804-11.. Harvoni. ). Prepared by: . David H. Spach, MD and H. Nina Kim, MD MSc. Last . Updated: . December 15, 2015. Background and Dosing. Ledipasvir-Sofosbuvir (. Harvoni. ). Ledipasvir-Sofosbuvir (. Harvoni. . or 3 . LONESTAR-2. Phase 2. Treatment. . Experienced. Lawitz. . E, et al. . Hepatology. . 2015:61:769-75.. Source: . Lawitz. E, et al. . Hepatology. . . 2015:61:769-75.. Sofosbuvir + . PEG + RBV . ASTRAL-2*. Phase 3. . Treatment. . Naïve & Experienced. Foster GR, . et al. . N . Engl. J Med. . 2015. ;373:2608-17.. *Published in tandem with ASTRAL-3 Trial. Source: Foster GR, . et al. N . ). Slide deck prepared . by: . David H. Spach, MD and H. Nina Kim, MD MSc. Last . Updated: . October 23, . 2014. Robe. rt G. Gish MD. Professor, Consultant, Stanford University Medical Center. Senior Medical Director, St Josephs Hospital and Medical Center, Liver Program, Phoenix, Arizona. NIAID Retreatment. Phase . 2a . Treatment. . Experienced. Osinusi. A, . et al. . Ann Intern Med. 2014;161:634-8.. Source: . Osinusi. A, et al. Ann Intern Med. 2014;161:634-8.. Ledipasvir-Sofosbuvir Retreatment of SOF RBV Failure in HCV GT 1. Sofosbuvir + Ribavirin to Prevent Post-Transplant HCV Recurrence Phase 2 Curry MP, et al. Gastroenterology . 2015;148:100-7. Treatment Naïve and Treatment Experienced Liver Transplantation Source: Curry MP, et for 12 weeks in liver transplant recipients with genotype 1-4. Agarwal K. J . Hepatol. . 2018;69:603-7. SOF/VEL: 400/100 mg 1 . tablet. QD. Liver transplant recipients. Recurrent HCV infection after transplantation. Kristen M. Marks, MD. Assistant Professor. Weill Cornell Medical College . New York, New York. Financial Relationships With Commercial Entities. Dr Marks was awarded research grants, paid to her institution, from Bristol-Myers Squibb, Gilead Sciences, .